Metabolic orchestration of drug-tolerant persister cells in cancer

References

[1] Sharma SV , Lee DY , Li B , et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010; 141: 69- 80.

[2] Russo M , Chen M , Mariella E , et al. Cancer drug-tolerant persister cells: from biological questions to clinical opportunities. Nat Rev Cancer 2024; 24: 694- 717.

[3] Raha D , Wilson TR , Peng J , et al. The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation. Cancer Res 2014; 74: 3579- 90.

[4] Hangauer MJ , Viswanathan VS , Ryan MJ , et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature 2017; 551: 247- 50.

[5] Shen S , Faouzi S , Souquere S , et al. Melanoma persister cells are tolerant to BRAF/MEK inhibitors via ACOX1-mediated fatty acid oxidation. Cell Rep 2020; 33: 108421.

[6] Oren Y , Tsabar M , Cuoco MS , et al. Cycling cancer persister cells arise from lineages with distinct programs. Nature 2021; 596: 576- 82.

[7] Rehman SK , Haynes J , Collignon E , et al. Colorectal cancer cells enter a diapause-like DTP state to survive chemotherapy. Cell 2021; 184: 226- 42.e21.

[8] van der Weijden VA , Stötzel M , Iyer DP , et al. FOXO1-mediated lipid metabolism maintains mammalian embryos in dormancy. Nat Cell Biol 2024; 26: 181- 93.

[9] Franca GS , Baron M , King BR , et al. Cellular adaptation to cancer therapy along a resistance continuum. Nature 2024; 631: 876- 83.

[10] Nie M , Chen N , Pang H , et al. Targeting acetylcholine signaling modulates persistent drug tolerance in EGFR-mutant lung cancer and impedes tumor relapse. J Clin Invest 2022; 132: e160152.

RIGHTS & PERMISSIONS

2024 The Author(s). Published by Oxford University Press on behalf of Higher Education Press.